AI-generated analysis. Always verify with the original filing.
Talphera, Inc. issued a press release announcing fourth quarter and full year 2025 financial results, including Q4 net loss of $3.8 million ($0.06 per share), full year net loss of $14.3 million ($0.34 per share), and cash and investments of $20.4 million as of December 31, 2025. The company reported 50% enrollment in the NEPHRO CRRT study, closure of a $4.1 million financing tranche, and 2026 cash operating expenses guidance of $17-18 million excluding stock-based compensation.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated March 23, 2026 104 Cover Page Interactive Data File (embedded within the Inli
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.00 | GAAP |
| Net Loss | $-3.80 | GAAP |
| Net Loss per Share, Basic and Diluted | $-0.06 | GAAP |
Cash operating expenses excluding stock-based compensation
1718
Non-GAAP